Contraceptives Based on SP22 and SP22 Antibodies
OwnerGary R. Klinefelterinventor
Life of this patent
Estimating the term…
Abstract
Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.
Claims40
A pharmaceutical composition comprising an effective anti-fertility amount of an antibody that binds to SP22 (SEQ ID NO:
- 2) and a pharmaceutically acceptable carrier.
A method of preventing conception, comprising contacting male ejaculate, prior to contact with a female egg, with an effective anti-fertility amount of a pharmaceutical composition, which comprises an antibody that binds to SP22 (SEQ ID NO:2) and a pharmaceutically acceptable carrier.
A vaccine comprising an SP22 (SEQ ID NO:
- 2) polypeptide and a pharmaceutically acceptable carrier.
A method for detecting infertility in a male subject comprising detecting the SP22 level of the male subject's sperm, wherein a decreased level of SP22 relative to the normal level indicates that the male subject is infertile.
A method for monitoring fertility status in a subject undergoing SP22 vaccination comprising detecting SP22 antibody level in said subject, wherein an increased level of SP22 antibody indicates that the subject is protected against fertilization.
Dependencies are inferred from the claim text.